Anixa Biosciences Inc ANIX revenue by segment, product and geography
Anixa Biosciences Inc's fiscal year ending 2025-10-31 carries a reported breakdown by business segments.
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Cancer Vaccines-$7.39M62.1%-8.0% yoy
- Cart Therapeutics-$4.45M37.4%-22.3% yoy
- Other-$54K0.5%-10.0% yoy
Members sum to the consolidated -$11.7M for this period.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.